Klinikum Itzehoe
- Address
- Robert-Koch-Straße 2, 25524 Itzehoe, Germany
Klinikum Itzehoe - Neonatal Respiratory Care Research
Klinikum Itzehoe is actively engaged in advancing neonatal care through specialized clinical research focused on respiratory distress syndrome in premature infants. The center demonstrates particular expertise in investigating innovative interventions for vulnerable preterm populations requiring advanced respiratory support during the critical early stages of life.
- Less Invasive Surfactant Administration (LISA) techniques in preterm neonates
- Prophylactic versus selective treatment approaches for respiratory distress syndrome
- Long-term pulmonary outcomes in extremely premature infants (25-30 weeks gestational age)
The center's research program emphasizes comprehensive long-term follow-up, tracking pulmonary function outcomes such as forced expiratory volume (FEV1) through early childhood. This commitment to evaluating both immediate neonatal interventions and their lasting impact on respiratory health demonstrates Klinikum Itzehoe's dedication to evidence-based neonatology and improving quality of life for premature infants well beyond their initial hospitalization.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 of 2 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Inmunotek S.L.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Itzehoe
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study of Subcutaneous Mannan-Conjugated Betula Pendula Pollen Allergoid in Birch Pollen-Induced Allergic Rhinitis | CCDRD Cooperative Clinical Drug Research and Development AG, ClinCompetence Cologne GmbH, Inmunotek S.L. | Phase III | Not Recruiting | Feb 2024 | Jun 2024 |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Betula Pendula Pollen Allergoid, Mannan-Conjugated, Polymerised | 2 | Unknown | 2024-02-26 | 2024-10-28 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.